Harvest Management LLC Invests $489,000 in Hologic, Inc. $HOLX

Harvest Management LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 7,500 shares of the medical equipment provider’s stock, valued at approximately $489,000. Hologic accounts for about 0.2% of Harvest Management LLC’s portfolio, making the stock its 27th largest holding.

A number of other institutional investors also recently bought and sold shares of HOLX. Invesco Ltd. raised its holdings in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after acquiring an additional 3,505,828 shares during the last quarter. United Services Automobile Association purchased a new position in shares of Hologic during the first quarter valued at approximately $347,000. K.J. Harrison & Partners Inc acquired a new stake in Hologic during the second quarter worth approximately $1,987,000. Aberdeen Group plc grew its stake in Hologic by 2.8% in the 2nd quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after acquiring an additional 6,589 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Hologic by 7.2% in the 2nd quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after acquiring an additional 174,828 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX opened at $74.83 on Thursday. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $77.32. The company has a 50 day moving average of $72.74 and a two-hundred day moving average of $68.11. The company has a market cap of $16.68 billion, a P/E ratio of 30.17, a P/E/G ratio of 2.12 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the firm posted $1.01 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. BNP Paribas Exane downgraded Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a research report on Friday, November 21st. Morgan Stanley upped their price objective on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Argus boosted their target price on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Five analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $79.29.

Insider Activity at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.